JPWO2020056074A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020056074A5 JPWO2020056074A5 JP2021513960A JP2021513960A JPWO2020056074A5 JP WO2020056074 A5 JPWO2020056074 A5 JP WO2020056074A5 JP 2021513960 A JP2021513960 A JP 2021513960A JP 2021513960 A JP2021513960 A JP 2021513960A JP WO2020056074 A5 JPWO2020056074 A5 JP WO2020056074A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- salt
- cycloalkyl
- alkoxy
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- -1 C 1-3 deuteroalkoxy Chemical group 0.000 claims 4
- 125000005345 deuteroalkyl group Chemical group 0.000 claims 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 3
- 125000006712 (C1-C4) deuteroalkyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 1
- 102000005403 Casein Kinases Human genes 0.000 claims 1
- 108010031425 Casein Kinases Proteins 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000005347 halocycloalkyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730611P | 2018-09-13 | 2018-09-13 | |
| US62/730,611 | 2018-09-13 | ||
| PCT/US2019/050721 WO2020056074A1 (en) | 2018-09-13 | 2019-09-12 | Indazole carboxamides as kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501334A JP2022501334A (ja) | 2022-01-06 |
| JPWO2020056074A5 true JPWO2020056074A5 (enExample) | 2022-09-05 |
| JP7434294B2 JP7434294B2 (ja) | 2024-02-20 |
Family
ID=68073172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513960A Active JP7434294B2 (ja) | 2018-09-13 | 2019-09-12 | キナーゼ阻害剤としてのインダゾールカルボキサミド |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12084426B2 (enExample) |
| EP (1) | EP3849969B1 (enExample) |
| JP (1) | JP7434294B2 (enExample) |
| KR (1) | KR102793119B1 (enExample) |
| CN (1) | CN112673001B (enExample) |
| AU (1) | AU2019339355A1 (enExample) |
| BR (1) | BR112021004310A2 (enExample) |
| CA (1) | CA3112519A1 (enExample) |
| EA (1) | EA202190759A1 (enExample) |
| ES (1) | ES2945220T3 (enExample) |
| IL (1) | IL281371A (enExample) |
| MX (1) | MX2021002617A (enExample) |
| SG (1) | SG11202102406XA (enExample) |
| WO (1) | WO2020056074A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3704118T1 (sl) | 2017-10-30 | 2022-04-29 | Bristol-Myers Squibb Company | Aminoimidazopiridazini kot kinazni inhibitorji |
| EA202091777A1 (ru) | 2018-01-26 | 2020-10-14 | Бристол-Маерс Сквибб Компани | Аминопирролотриазины в качестве ингибиторов киназы |
| AU2019337612A1 (en) * | 2018-09-13 | 2021-05-13 | Bristol-Myers Squibb Company | 1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1) |
| CN112673001B (zh) | 2018-09-13 | 2024-06-25 | 百时美施贵宝公司 | 作为激酶抑制剂的吲唑甲酰胺 |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| MX2022003769A (es) * | 2019-10-03 | 2022-04-20 | Bristol Myers Squibb Co | Indazol carboxamidas como inhibidores de cinasas. |
| AR123793A1 (es) | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
| WO2023119210A1 (ko) | 2021-12-24 | 2023-06-29 | 제일약품주식회사 | Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7872014B2 (en) | 2003-07-23 | 2011-01-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| CA2591817A1 (en) | 2004-12-22 | 2006-06-29 | Memory Pharmaceuticals Corporation | Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
| HRP20110917T1 (hr) | 2006-05-19 | 2012-03-31 | Abbott Laboratories | Derivati azabicikličkih alkana supstituirani fuzioniranim bicikloheterociklima aktivni u središnjem živčanom sustavu |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| KR101061599B1 (ko) | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| WO2010068287A2 (en) | 2008-12-11 | 2010-06-17 | Angion Biomedica Corp. | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| US8455516B2 (en) | 2010-01-15 | 2013-06-04 | Touro University | HIV-1 fusion inhibitors and methods |
| KR20130077390A (ko) * | 2011-12-29 | 2013-07-09 | 제이더블유중외제약 주식회사 | 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체 |
| ES2564961T3 (es) | 2012-02-21 | 2016-03-30 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Compuestos de 1H-indazol-3-carboxamida como inhibidores de la glucógeno sintasa cinasa 3 beta |
| ES2564033T3 (es) | 2012-02-21 | 2016-03-17 | Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.P.A. | Utilización de compuestos de 1H-indazol-3-carboxamida como inhibidores de la glucógeno sintasa cinasa 3 beta |
| WO2014047024A1 (en) | 2012-09-18 | 2014-03-27 | Bristol-Myers Squibb Company | Iap antagonists |
| EP3463355B1 (en) | 2016-05-26 | 2024-08-28 | Sonic Master Limited | Modulators of dux4 for regulation of muscle function |
| MA46453A (fr) * | 2016-10-07 | 2019-08-14 | Bristol Myers Squibb Co | Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha |
| HUE057801T2 (hu) | 2017-02-13 | 2022-06-28 | Bristol Myers Squibb Co | Aminotriazolopiridinek mint kináz inhibitorok |
| SI3704118T1 (sl) | 2017-10-30 | 2022-04-29 | Bristol-Myers Squibb Company | Aminoimidazopiridazini kot kinazni inhibitorji |
| EA202091777A1 (ru) | 2018-01-26 | 2020-10-14 | Бристол-Маерс Сквибб Компани | Аминопирролотриазины в качестве ингибиторов киназы |
| CN112673001B (zh) | 2018-09-13 | 2024-06-25 | 百时美施贵宝公司 | 作为激酶抑制剂的吲唑甲酰胺 |
| AU2019337612A1 (en) | 2018-09-13 | 2021-05-13 | Bristol-Myers Squibb Company | 1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1) |
| MX2022003769A (es) | 2019-10-03 | 2022-04-20 | Bristol Myers Squibb Co | Indazol carboxamidas como inhibidores de cinasas. |
-
2019
- 2019-09-12 CN CN201980059544.6A patent/CN112673001B/zh active Active
- 2019-09-12 US US17/274,227 patent/US12084426B2/en active Active
- 2019-09-12 EP EP19779242.7A patent/EP3849969B1/en active Active
- 2019-09-12 AU AU2019339355A patent/AU2019339355A1/en not_active Abandoned
- 2019-09-12 BR BR112021004310-1A patent/BR112021004310A2/pt not_active Application Discontinuation
- 2019-09-12 WO PCT/US2019/050721 patent/WO2020056074A1/en not_active Ceased
- 2019-09-12 ES ES19779242T patent/ES2945220T3/es active Active
- 2019-09-12 SG SG11202102406XA patent/SG11202102406XA/en unknown
- 2019-09-12 CA CA3112519A patent/CA3112519A1/en active Pending
- 2019-09-12 EA EA202190759A patent/EA202190759A1/ru unknown
- 2019-09-12 KR KR1020217010495A patent/KR102793119B1/ko active Active
- 2019-09-12 MX MX2021002617A patent/MX2021002617A/es unknown
- 2019-09-12 JP JP2021513960A patent/JP7434294B2/ja active Active
-
2021
- 2021-03-09 IL IL281371A patent/IL281371A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2686323C2 (ru) | Новые соединения и композиции для ингибирования fasn | |
| JPWO2022177917A5 (enExample) | ||
| EP3277276B1 (en) | Methods of administering glutaminase inhibitors | |
| JP2019094345A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| IL205501A (en) | Preparation of preparations for the treatment of arthritis | |
| JP2018168191A5 (enExample) | ||
| NO20056007L (no) | Dobbel NK1/NK3 antagonister for behandling av schizofreni | |
| JP2019507114A5 (enExample) | ||
| JP2015536986A5 (enExample) | ||
| JP2010527985A5 (enExample) | ||
| RU2017110211A (ru) | ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ-ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ | |
| US8440675B2 (en) | Potentiator of radiation therapy | |
| WO2021016333A1 (en) | Aryl sulfonamides as small molecule stat3 inhibitors | |
| JPWO2020056074A5 (enExample) | ||
| MX2023010141A (es) | Derivados de benzo[c][2,6]naftiridina, composiciones y usos terapeuticos de los mismos. | |
| TW202313050A (zh) | 組合療法 | |
| CN102924443B (zh) | 含有杂环的5-羟基吲哚类衍生物及其用途 | |
| JP2005527575A5 (enExample) | ||
| CN111836801A (zh) | 用于抑制tnik的化合物及其医疗用途 | |
| JPWO2021041237A5 (enExample) | ||
| EA029044B1 (ru) | Соединения метантиона, обладающие противовирусной активностью | |
| AU2020358643A1 (en) | 4-quinolinone antibacterial compounds | |
| JP2007507467A5 (enExample) | ||
| JPWO2021119523A5 (enExample) |